Compare AQMS & ANEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AQMS | ANEB |
|---|---|---|
| Founded | 2014 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.9M | 19.4M |
| IPO Year | 2015 | 2021 |
| Metric | AQMS | ANEB |
|---|---|---|
| Price | $5.06 | $0.43 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | ★ 82.2K | 78.7K |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.88 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,100,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $550.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $0.41 |
| 52 Week High | $39.37 | $3.42 |
| Indicator | AQMS | ANEB |
|---|---|---|
| Relative Strength Index (RSI) | 43.75 | 19.46 |
| Support Level | $4.62 | N/A |
| Resistance Level | $8.37 | $1.27 |
| Average True Range (ATR) | 0.34 | 0.06 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 72.29 | 2.70 |
Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting, and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.